Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CH:BIOV
Stock Latest News
Company Announcements
BioVersys strengthens BV100 case with Phase 1 lung penetration and interaction data
44s ago
BIOV
Premium
Company Announcements
BioVersys Advances Late-Stage Antibiotic Pipeline and Extends Funding Runway to 2028
1M ago
BIOV
Premium
Company Announcements
BioVersys Showcases MDR Antibiotic Pipeline at H.C. Wainwright Global Investment Conference
2M ago
BIOV
Premium
Company Announcements
BioVersys Wins FDA Fast Track for Lead Antibiotic BV100
2M ago
BIOV
Premium
Company Announcements
BioVersys schedules half-year results and investor update as late-stage antibacterial pipeline advances
2M ago
BIOV
Premium
Company Announcements
BioVersys Sets September 9 Date for Half-Year 2026 Results and Strategic Update
2M ago
BIOV
Premium
Company Announcements
BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
6M ago
BIOV
Premium
Company Announcements
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
6M ago
BIOV
Premium
Ratings
Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
6M ago
Premium
Company Announcements
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
6M ago
BIOV
Premium
Company Announcements
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
6M ago
BIOV
Premium
Ratings
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
6M ago
Premium
Company Announcements
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
6M ago
BIOV
Premium
Company Announcements
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
7M ago
BIOV
Premium
Company Announcements
BioVersys Strengthens Investor Outreach With New IR and Communications Head
7M ago
BIOV
Premium
Ratings
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
7M ago
Premium
Company Announcements
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
7M ago
BIOV
Premium
Company Announcements
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
7M ago
BIOV
Premium
Ratings
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
7M ago
Premium
Company Announcements
BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
7M ago
BIOV
Premium
Ratings
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
7M ago
Premium
Company Announcements
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
7M ago
BIOV
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
